HC Wainwright Has Bearish Outlook for NeuroPace Q2 Earnings

NeuroPace, Inc. (NASDAQ:NPCE) – Analysts at HC Wainwright decreased their Q2 2026 earnings estimates for NeuroPace in a research note issued on Friday, May 15th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($0.21) for the quarter, down from their prior forecast of ($0.20). HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for NeuroPace’s current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for NeuroPace’s Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.12) EPS and FY2027 earnings at $0.10 EPS.

Other equities analysts have also issued reports about the stock. Wall Street Zen lowered shares of NeuroPace from a “buy” rating to a “hold” rating in a research report on Sunday, March 15th. Cantor Fitzgerald raised shares of NeuroPace to a “strong-buy” rating in a research report on Wednesday, March 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of NeuroPace in a report on Friday, March 27th. Finally, Wells Fargo & Company upgraded shares of NeuroPace to a “strong-buy” rating in a research report on Wednesday, March 18th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $18.83.

NeuroPace Price Performance

NASDAQ:NPCE opened at $15.99 on Tuesday. NeuroPace has a 52 week low of $7.56 and a 52 week high of $19.60. The firm has a market cap of $545.10 million, a price-to-earnings ratio of -24.60 and a beta of 1.92. The firm’s 50-day simple moving average is $15.16 and its 200 day simple moving average is $15.14. The company has a debt-to-equity ratio of 4.08, a quick ratio of 4.35 and a current ratio of 5.38.

NeuroPace (NASDAQ:NPCE) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.06. NeuroPace had a negative net margin of 21.67% and a negative return on equity of 108.20%. The firm had revenue of $22.00 million during the quarter, compared to analysts’ expectations of $21.65 million.

Hedge Funds Weigh In On NeuroPace

Several hedge funds and other institutional investors have recently made changes to their positions in NPCE. First Light Asset Management LLC raised its position in shares of NeuroPace by 82.3% in the 1st quarter. First Light Asset Management LLC now owns 2,459,966 shares of the company’s stock valued at $32,349,000 after buying an additional 1,110,484 shares in the last quarter. Kotler Kevin bought a new stake in shares of NeuroPace during the 4th quarter valued at approximately $9,750,000. Walleye Capital LLC grew its holdings in shares of NeuroPace by 344.6% during the 4th quarter. Walleye Capital LLC now owns 228,847 shares of the company’s stock valued at $3,533,000 after purchasing an additional 177,375 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of NeuroPace by 44.6% during the 2nd quarter. Geode Capital Management LLC now owns 485,162 shares of the company’s stock valued at $5,406,000 after purchasing an additional 149,595 shares during the last quarter. Finally, Armistice Capital LLC grew its holdings in shares of NeuroPace by 12.6% during the 3rd quarter. Armistice Capital LLC now owns 1,298,000 shares of the company’s stock valued at $13,382,000 after purchasing an additional 145,665 shares during the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

NeuroPace Company Profile

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.